FDA's Dominance Shapes European Gene Therapy Outlook at Rome Industry Summit

At a premier biotechnology summit in Rome, industry leaders converged to discuss the future of the European cell and gene therapy landscape. However, the discourse was heavily dictated by the overwhelming influence of the United States Food and Drug Administration (FDA). Experts noted that the American regulatory environment, characterized by faster approval pathways and a more unified market, is increasingly drawing investment and clinical focus away from Europe. The discussion highlighted a critical 'infrastructure gap' and the bureaucratic hurdles of the European fragmented reimbursement system, which force developers to prioritize US markets. As the European Union considers significant reforms to its pharmaceutical legislation, the summit emphasized the urgent need for structural changes to remain globally competitive. The prevailing sentiment is one of cautious realism: unless Europe streamlines its regulatory processes and incentivizes domestic manufacturing, it risks falling further behind the US in the race to bring life-saving genomic medicines to patients.